3/21
12:34 pm
idya
IDEAYA Biosciences, Inc. (NASDAQ: IDYA) had its price target raised by analysts at Citigroup Inc. from $40.00 to $60.00. They now have a "buy" rating on the stock.
Low
Report
IDEAYA Biosciences, Inc. (NASDAQ: IDYA) had its price target raised by analysts at Citigroup Inc. from $40.00 to $60.00. They now have a "buy" rating on the stock.
3/12
06:00 am
idya
IDEAYA Announces Clinical Collaboration to Evaluate IDE161 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Endometrial Cancer
Low
Report
IDEAYA Announces Clinical Collaboration to Evaluate IDE161 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Endometrial Cancer
3/8
08:23 am
idya
IDEAYA Biosciences, Inc. (NASDAQ: IDYA) is now covered by analysts at BTIG Research. They set a "buy" rating and a $55.00 price target on the stock.
Low
Report
IDEAYA Biosciences, Inc. (NASDAQ: IDYA) is now covered by analysts at BTIG Research. They set a "buy" rating and a $55.00 price target on the stock.
3/4
06:13 am
idya
IDEAYA Biosciences to Participate in Upcoming March 2024 Investor Relations Events [Yahoo! Finance]
Medium
Report
IDEAYA Biosciences to Participate in Upcoming March 2024 Investor Relations Events [Yahoo! Finance]
3/4
06:00 am
idya
IDEAYA Biosciences to Participate in Upcoming March 2024 Investor Relations Events
Medium
Report
IDEAYA Biosciences to Participate in Upcoming March 2024 Investor Relations Events
2/29
07:35 am
idya
IDEAYA Biosciences, Inc. (NASDAQ: IDYA) had its "outperform" rating re-affirmed by analysts at Leerink Partnrs.
Low
Report
IDEAYA Biosciences, Inc. (NASDAQ: IDYA) had its "outperform" rating re-affirmed by analysts at Leerink Partnrs.
2/23
01:09 pm
idya
IDEAYA Biosciences, Inc. (NASDAQ: IDYA) had its price target raised by analysts at JPMorgan Chase & Co. from $51.00 to $57.00. They now have an "overweight" rating on the stock.
Low
Report
IDEAYA Biosciences, Inc. (NASDAQ: IDYA) had its price target raised by analysts at JPMorgan Chase & Co. from $51.00 to $57.00. They now have an "overweight" rating on the stock.
2/23
06:33 am
idya
IDEAYA Biosciences, Inc. (NASDAQ: IDYA) had its "overweight" rating re-affirmed by analysts at Capital One Financial Co..
Medium
Report
IDEAYA Biosciences, Inc. (NASDAQ: IDYA) had its "overweight" rating re-affirmed by analysts at Capital One Financial Co..
2/23
06:12 am
idya
IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Analysts Are Pretty Bullish On The Stock After Recent Results [Yahoo! Finance]
Medium
Report
IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Analysts Are Pretty Bullish On The Stock After Recent Results [Yahoo! Finance]
2/21
10:23 am
idya
IDEAYA Biosciences, Inc. (NASDAQ: IDYA) had its price target raised by analysts at Royal Bank of Canada from $43.00 to $53.00. They now have an "outperform" rating on the stock.
Low
Report
IDEAYA Biosciences, Inc. (NASDAQ: IDYA) had its price target raised by analysts at Royal Bank of Canada from $43.00 to $53.00. They now have an "outperform" rating on the stock.
2/20
06:03 am
idya
IDEAYA Biosciences, Inc. Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update [Yahoo! Finance]
Medium
Report
IDEAYA Biosciences, Inc. Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update [Yahoo! Finance]
2/20
06:00 am
idya
IDEAYA Biosciences, Inc. Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update
Medium
Report
IDEAYA Biosciences, Inc. Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update
2/16
01:26 pm
idya
Ideaya Biosciences: A Strong Bet In Targeted Oncology [Seeking Alpha]
Low
Report
Ideaya Biosciences: A Strong Bet In Targeted Oncology [Seeking Alpha]
2/13
05:53 am
idya
IDEAYA Biosciences Inc CEO Yujiro Hata Sells 99,372 Shares [Yahoo! Finance]
Medium
Report
IDEAYA Biosciences Inc CEO Yujiro Hata Sells 99,372 Shares [Yahoo! Finance]
2/1
06:00 am
idya
IDEAYA Biosciences to Participate in Upcoming February 2024 Investor Relations Events
Low
Report
IDEAYA Biosciences to Participate in Upcoming February 2024 Investor Relations Events
1/29
07:23 am
idya
IDEAYA Biosciences, Inc. (NASDAQ:IDYA) is largely controlled by institutional shareholders who own 77% of the company [Yahoo! Finance]
Medium
Report
IDEAYA Biosciences, Inc. (NASDAQ:IDYA) is largely controlled by institutional shareholders who own 77% of the company [Yahoo! Finance]
1/26
06:00 am
idya
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Low
Report
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
1/25
09:32 am
idya
IDEAYA Biosciences, Inc. (NASDAQ: IDYA) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $36.00 to $53.00. They now have a "buy" rating on the stock.
Low
Report
IDEAYA Biosciences, Inc. (NASDAQ: IDYA) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $36.00 to $53.00. They now have a "buy" rating on the stock.
1/18
08:19 am
idya
IDEAYA Biosciences Inc President and CEO Yujiro Hata Sells 75,000 Shares [Yahoo! Finance]
Low
Report
IDEAYA Biosciences Inc President and CEO Yujiro Hata Sells 75,000 Shares [Yahoo! Finance]
1/15
08:27 am
idya
IDEAYA Biosciences, Inc. (IDYA) Moves 7.6% Higher: Will This Strength Last? [Yahoo! Finance]
Low
Report
IDEAYA Biosciences, Inc. (IDYA) Moves 7.6% Higher: Will This Strength Last? [Yahoo! Finance]
1/10
10:18 am
idya
IDEAYA Biosciences, Inc. (NASDAQ: IDYA) had its price target raised by analysts at Royal Bank of Canada from $36.00 to $43.00. They now have an "outperform" rating on the stock.
Low
Report
IDEAYA Biosciences, Inc. (NASDAQ: IDYA) had its price target raised by analysts at Royal Bank of Canada from $36.00 to $43.00. They now have an "outperform" rating on the stock.
1/7
09:00 am
idya
IDEAYA Biosciences Announces Participation at the 42nd Annual J.P. Morgan Healthcare Conference and 2024 Corporate Guidance
Medium
Report
IDEAYA Biosciences Announces Participation at the 42nd Annual J.P. Morgan Healthcare Conference and 2024 Corporate Guidance